Tango Therapeutics Inc (TNGX)

$6.55

-0.23

(-3.39%)▲

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $6.33
    $6.75
    $6.55
    downward going graph

    3.36%

    Downside

    Day's Volatility :6.22%

    Upside

    2.96%

    downward going graph
  • $5.15
    $13.01
    $6.55
    downward going graph

    21.37%

    Downside

    52 Weeks Volatility :60.4%

    Upside

    49.63%

    downward going graph

Returns

PeriodTango Therapeutics IncIndex (Russel 2000)
3 Months
-31.84%
0.0%
6 Months
-13.7%
0.0%
1 Year
-25.99%
0.0%
3 Years
-51.55%
-20.3%

Highlights

Market Capitalization
726.4M
Book Value
$2.31
Earnings Per Share (EPS)
-1.11
Wall Street Target Price
16.13
Profit Margin
-274.04%
Operating Margin TTM
-148.69%
Return On Assets TTM
-21.76%
Return On Equity TTM
-50.58%
Revenue TTM
42.5M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
36.1%
Gross Profit TTM
-81.0M
EBITDA
-130.0M
Diluted Eps TTM
-1.11
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.33
EPS Estimate Next Year
-1.46
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Tango Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 146.26%

Current $6.55
Target $16.13

Company Financials

FY19Y/Y Change
Revenue
24.6M
-
Net Income
-14.1M
-
Net Profit Margin
-57.18%
-
FY20Y/Y Change
Revenue
7.7M
↓ 68.94%
Net Income
-51.9M
↑ 267.96%
Net Profit Margin
-677.43%
↓ 620.25%
FY21Y/Y Change
Revenue
37.0M
↑ 383.83%
Net Income
-58.2M
↑ 12.28%
Net Profit Margin
-157.21%
↑ 520.22%
FY22Y/Y Change
Revenue
24.9M
↓ 32.89%
Net Income
-108.2M
↑ 85.76%
Net Profit Margin
-435.14%
↓ 277.93%
FY23Y/Y Change
Revenue
36.5M
↑ 46.93%
Net Income
-101.7M
↓ 5.95%
Net Profit Margin
-278.54%
↑ 156.6%
Q1 FY23Q/Q Change
Revenue
5.8M
↓ 10.06%
Net Income
-25.7M
↓ 11.46%
Net Profit Margin
-446.24%
↑ 7.04%
Q2 FY23Q/Q Change
Revenue
14.6M
↑ 153.17%
Net Income
-20.7M
↓ 19.51%
Net Profit Margin
-141.87%
↑ 304.37%
Q3 FY23Q/Q Change
Revenue
10.7M
↓ 26.48%
Net Income
-22.3M
↑ 7.5%
Net Profit Margin
-207.45%
↓ 65.58%
Q4 FY23Q/Q Change
Revenue
5.4M
↓ 49.39%
Net Income
-30.8M
↑ 38.18%
Net Profit Margin
-566.43%
↓ 358.98%
Q1 FY24Q/Q Change
Revenue
6.5M
↑ 19.15%
Net Income
-37.9M
↑ 23.25%
Net Profit Margin
-585.91%
↓ 19.48%
Q2 FY24Q/Q Change
Revenue
19.9M
↑ 207.14%
Net Income
-25.6M
↓ 32.61%
Net Profit Margin
-128.56%
↑ 457.35%
FY19Y/Y Change
Total Assets
55.8M
-
Total Liabilities
47.9M
-
FY20Y/Y Change
Total Assets
207.3M
↑ 271.66%
Total Liabilities
168.7M
↑ 252.39%
FY21Y/Y Change
Total Assets
500.2M
↑ 141.33%
Total Liabilities
155.4M
↓ 7.85%
FY22Y/Y Change
Total Assets
436.5M
↓ 12.73%
Total Liabilities
187.0M
↑ 20.32%
FY23Y/Y Change
Total Assets
402.6M
↓ 7.77%
Total Liabilities
149.5M
↓ 20.07%
Q1 FY23Q/Q Change
Total Assets
403.8M
↓ 7.49%
Total Liabilities
176.5M
↓ 5.61%
Q2 FY23Q/Q Change
Total Assets
379.3M
↓ 6.05%
Total Liabilities
166.4M
↓ 5.74%
Q3 FY23Q/Q Change
Total Assets
428.2M
↑ 12.88%
Total Liabilities
151.6M
↓ 8.89%
Q4 FY23Q/Q Change
Total Assets
402.6M
↓ 5.98%
Total Liabilities
149.5M
↓ 1.41%
Q1 FY24Q/Q Change
Total Assets
406.2M
↑ 0.91%
Total Liabilities
141.8M
↓ 5.14%
Q2 FY24Q/Q Change
Total Assets
381.5M
↓ 6.1%
Total Liabilities
133.8M
↓ 5.64%
FY19Y/Y Change
Operating Cash Flow
-24.8M
-
Investing Cash Flow
848.0K
-
Financing Cash Flow
11.0M
-
FY20Y/Y Change
Operating Cash Flow
70.1M
↓ 382.52%
Investing Cash Flow
-145.5M
↓ 17254.01%
Financing Cash Flow
80.9M
↑ 635.31%
FY21Y/Y Change
Operating Cash Flow
-59.5M
↓ 184.95%
Investing Cash Flow
-183.4M
↑ 26.1%
Financing Cash Flow
357.3M
↑ 341.77%
FY22Y/Y Change
Operating Cash Flow
-109.1M
↑ 83.24%
Investing Cash Flow
26.4M
↓ 114.39%
Financing Cash Flow
1.6M
↓ 99.55%
Q1 FY23Q/Q Change
Operating Cash Flow
-34.9M
↑ 23.49%
Investing Cash Flow
31.6M
↓ 350.31%
Financing Cash Flow
73.0K
↓ 86.15%

Technicals Summary

Sell

Neutral

Buy

Tango Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tango Therapeutics Inc
Tango Therapeutics Inc
-32.4%
-13.7%
-25.99%
-51.55%
-34.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.48%
8.55%
19.49%
82.88%
232.15%
Novo Nordisk A/s
Novo Nordisk A/s
-13.09%
-6.28%
18.91%
138.88%
358.83%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.38%
83.19%
66.02%
36.22%
252.82%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.3%
18.97%
30.36%
165.15%
176.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tango Therapeutics Inc
Tango Therapeutics Inc
NA
NA
NA
-1.33
-0.51
-0.22
NA
2.31
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.04
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.53
39.53
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tango Therapeutics Inc
Tango Therapeutics Inc
Buy
$726.4M
-34.43%
NA
-274.04%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
232.15%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$519.8B
358.83%
39.53
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.8B
252.82%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
176.17%
32.84
-4.74%

Insights on Tango Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 5.43M → 19.87M (in $), with an average increase of 41.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -37.91M → -25.55M (in $), with an average increase of 48.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.0% return, outperforming this stock by 92.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 36.2% return, outperforming this stock by 87.8%

Institutional Holdings

  • Wellington Management Company LLP

    0.14%

Company Information

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util

Organization
Tango Therapeutics Inc
Employees
140
CEO
Dr. Barbara L. Weber M.D.
Industry
Miscellaneous

Discover More

FAQs